Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Oncolytic herpes simplex virus diminishes mammary tumors in mice
April 14th, 2005
Oncolytic herpes simplex virus diminishes mammary tumors in mice. According to recent research published in the journal Cancer Research, "oncolytic herpes simplex virus vectors are a promising strategy for cancer therapy, as direct cytotoxic agents, inducers of antitumor immune responses, and as expressers of anticancer genes. Progress is dependent upon representative preclinical models to evaluate therapy." "In this study, two families of oncolytic herpes simplex virus vectors (G207 and NV1020 series) that have been in clinical trials were examined for the treatment of breast cancer, using the C3(1)/T-Ag transgenic mouse model," said R.B. Liu...
Source: Women's Health Weekly (2005-04-14)
|
